Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Botox won its fourth U.S. Food and Drug Administration approval yesterday, for the treatment of excessive sweating. Injections of the drug into the armpit seem to essentially paralyze the sweat glands; taking shots once or twice a year (at $1,000 to $2,000 a pop) seems to help patients with severe underarm sweating.

Specialty pharmaceutical maker Allergan has been riding the wave of what may turn out to be the first biotech “miracle drug,” with more applications than initially imagined. The protein therapeutic, a low concentration injection of the toxin that causes botulism food poisoning, has already been approved for the treatment of wrinkles and certain muscle spasms in the neck and eye. It is also being studied for the relief of migraines, muscle spasticity in cerebral palsy, muscle tightness in stroke patients, and involuntary movements such as those associated with Parkinson disease.

1 comment. Share your thoughts »

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me